MRK Merck & Co.

XNYS Sideways Alert

Health Care

· How we analyze

About the company

Merck & Co. is a major US pharmaceutical company, known as MSD outside North America. Its main drug is the cancer medicine Keytruda; it also makes vaccines such as Gardasil and animal health products. It is not related to the German Merck from Darmstadt. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Rahway, USA

According to the company, Merck & Co. is a global healthcare company with the segments Pharmaceutical and Animal Health. The pharmaceutical segment comprises human medicines and vaccines, including Keytruda and the Gardasil vaccine against certain papillomaviruses. The company supplies medicines mainly to wholesalers and retailers, hospitals, government agencies and managed care organizations, and vaccines mainly to physicians, distributors and government bodies. The Animal Health segment markets veterinary medicines and vaccines, for example Bravecto for parasite control and the antibiotic Nuflor for cattle and pigs. Customers are veterinarians, distributors, livestock producers, farmers and pet owners; in addition, there are digital products for identifying and monitoring animals.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

Price performance at a glance

Last 30 trading days
  • Today −3.2%
  • 7 days −2.1%
  • 30 days −5.5%
  • 1 year +60.7%
Day range (last trading day)
−0.5%Price at 10% of the range+4.3%
52-week range
−41.7%Price at 78% of the range+11.6%
Distance from the all-time high
−10.4%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Where is the price relative to the buy zone?

No buy zone

There is currently no buy zone for this symbol under our Elliott rule. One only forms when the price pulls back after a strong rise.

An observation, not investment advice

Rule (4-hour candles) No active buy zone – the last one ended on Oct 26, 2026 · Setup invalid (close below the start of wave 1)

Watcher Full history: every change of the buy zone with its date.

Automated analysis (rule-based)

How we analyze

Timeframe 4 hours · As of Oct 27, 2026

Elliott wave analysis Merck & (4-hour candles): Flat (type known only after C), Corrective pattern (downward), C in progress (3 of 3 guidelines); no buy zone of the rule on this timeframe. Candlestick chart MRK with 60 4-hour candles from Sep 15, 2026, 19:30 to Oct 27, 2026, 14:30. No buy zone of the rule on this timeframe – only the Elliott count: Flat (type known only after C), Corrective pattern (downward), C in progress (3 of 3 guidelines) (B = 103% of A; C = 96% of A), invalid on a close above the end of B. Fibonacci target zones for this count from Watcher. No value axis. Automated analysis (rule-based), not investment advice. MRK · 4-hour candles · Automated analysis (rule-based) No buy zone of the rule – Elliott count only Fibonacci target zones for this count from Watcher invalid on a close above the end of B 0 A B C in progress Sep 17 Sep 23 Sep 29 Oct 5 Oct 9 Oct 15 Oct 21 last candle Oct 27, 2026, 14:30 · not investment advice Without a buy zone of the rule: no value axis
  • 4-hour candles (green = close above open, red = below)
  • Elliott count (thin gold line, waves in circles; dashed circle = still in progress; small = subwaves; red dashed = invalidation level)
  • Watcher Fibonacci target zones for this count from Watcher

Elliott count: Flat (type known only after C), Corrective pattern (downward), C in progress (3 of 3 guidelines) · B = 103% of A; C = 96% of A

Note: Flat type (regular, expanded, running) can only be decided once C is complete.

Note: Structure ambiguous: leg A can also be read as three- or five-part.

Note: Retracement at least 88.7% of A: flat possible (B in progress, type only with C).

Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.

Scenarios

Timeframe 4 hours · As of Oct 27, 2026 · from the Elliott count in the analysis chart

Weighting Main scenario (3 of 3 guidelines, strong) · no alternative

Weighting by guidelines met – not a probability.

Main scenario

strong · 3 of 3 guidelines

As long as the 4-hour close stays below the end of B, this applies: flat countermove downward in three waves (Flat, type known only after C), C in progress – count points to falling prices.

Invalid if the 4-hour close is above the end of B

Alternative

If that breaks, this count no longer applies. Currently no alternative that follows the rules.

Watcher Fibonacci target zones and levels for this count – as a help for your own review – from Watcher.

Fundamental analysis

Merck & Co. · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 24, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+6.3% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+20.9% per year), at least as fast as the sector median; per share +21.2% per year.
  • Light green: Net margin 28.1%, above the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 39.8B USD · Net income 3.9B USD · Net margin 9.8%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 40.1B USD · Net income 2.4B USD · Net margin 6.0%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 42.3B USD · Net income 6.2B USD · Net margin 14.7%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 46.8B USD · Net income 9.8B USD · Net margin 21.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 48.0B USD · Net income 7.1B USD · Net margin 14.7%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 48.7B USD · Net income 13.0B USD · Net margin 26.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 59.3B USD · Net income 14.5B USD · Net margin 24.5%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 60.1B USD · Net income 365.0M USD · Net margin 0.6%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 64.2B USD · Net income 17.1B USD · Net margin 26.7%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.0B USD · Net income 18.3B USD · Net margin 28.1%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.0B USD · Net income 18.3B USD · Net margin 28.1%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+6.3% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 6.3% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+20.9% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +21.2% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 20.9% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.1% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 28.08 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 14.7%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

1.22 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 1.22 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

45% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.45 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
65.0B USD
Revenue vs. prior year
+1.3%
Net income (FY)
18.3B USD
Net income vs. prior year
+6.6%
EPS (FY)
7.28 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
−58.7%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Jun 30, 2026 (filed Aug 7, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 65.0B18.3B 28.1% 7.28 3.28 45%
2024Dec 31, 2024 64.2B17.1B 26.7% 6.74 3.12 46%
2023Dec 31, 2023 60.1B365.0M 0.6% 0.14 2.96 2,114%
2022Dec 31, 2022 59.3B14.5B 24.5% 5.71 2.80 49%
2021Dec 31, 2021 48.7B13.0B 26.8% 5.14 2.64 51%
2020Dec 31, 2020 48.0B7.1B 14.7% 2.78 2.48 89%
2019Dec 31, 2019 46.8B9.8B 21.0% 3.81 2.26 59%
2018Dec 31, 2018 42.3B6.2B 14.7% 2.32 1.99 86%
2017Dec 31, 2017 40.1B2.4B 6.0% 0.87 1.89 217%
2016Dec 31, 2016 39.8B3.9B 9.8% 1.41 1.85 131%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 16.6B−1.3B −8.0% −0.54 0.85 –
Q1/26Mar 31, 2026 16.3B−4.2B −26.0% −1.72 0.85 –
Q4/25*Dec 31, 2025 16.4B3.0B 18.1% – 0.85 –
Q3/25Sep 30, 2025 17.3B5.8B 33.5% 2.32 0.81 35%
Q2/25Jun 30, 2025 15.8B4.4B 28.0% 1.76 0.81 46%
Q1/25Mar 31, 2025 15.5B5.1B 32.7% 2.01 0.81 40%
Q4/24*Dec 31, 2024 15.6B3.7B 24.0% – 0.81 –
Q3/24Sep 30, 2024 16.7B3.2B 19.0% 1.24 0.77 62%
Q2/24Jun 30, 2024 16.1B5.5B 33.9% 2.14 0.77 36%
Q1/24Mar 31, 2024 15.8B4.8B 30.2% 1.87 0.77 41%
Q4/23*Dec 31, 2023 14.6B−1.2B −8.4% – 0.77 –
Q3/23Sep 30, 2023 16.0B4.7B 29.7% 1.86 0.73 39%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $30.0M5 people −$30.0M
6 months $00 people $30.0M5 people −$30.0M
12 months $00 people $72.0M11 people −$72.0M

Latest transactions

  • Aug 13, 2026 Guindo Chirfi Officer Open-market sale 10,000 shares · $1.4M · SEC
  • Aug 12, 2026 Zachary Jennifer Officer Open-market sale 80,315 shares · $10.7M · SEC
  • Aug 12, 2026 DeLuca Richard R. Officer Open-market sale 600 shares · $79.2K · SEC
  • Aug 12, 2026 DeLuca Richard R. Officer Open-market sale 11,099 shares · $1.5M · SEC
  • Aug 11, 2026 DeLuca Richard R. Officer Open-market sale 5,427 shares · $718.3K · SEC
  • Aug 11, 2026 DeLuca Richard R. Officer Open-market sale 7,410 shares · $973.2K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +25

Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)16.5
Rel. strength 60 d+6.2%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MRK yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MRK

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

↑ ↓ select · Enter open · Esc close